Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Erasca Inc. Common Stock (ERAS) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Erasca Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Erasca Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.73 (market cap $763.64M), while Erasca Inc. Common Stock trades at $15.64 (market cap $5.40B). The key difference: Erasca Inc. Common Stock is far larger — about 7.1× Ginkgo Bioworks Holdings Inc's market cap, and Erasca Inc. Common Stock is more actively traded (9,533,185 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Erasca Inc. Common Stock for 0 Days on average.

DNAERAS
Market Cap
$763.64M$5.40B
Volume
3,204,1779,533,185
Sector
HealthHealth
52-Week High
$15.83$22.47
52-Week Low
$5.48$2.20
Typical Hold Time
7 Days0 Days
Enterprise Value
$865.59M$5.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.

Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.

Erasca Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
ERAS
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About Erasca Inc. Common Stock

Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.

Read more on ERAS →